Skip to content

inbiome

inbiome

inbiome is a molecular diagnostics company at Amsterdam Science Park that is changing how bacterial infections are found and identified. Most hospitals still rely on culturing bacteria in the laboratory — a method more than a century old that takes two to five days and often fails entirely once a patient has received antibiotics. During that wait, physicians usually treat blindness with broad-spectrum antibiotics that may be unnecessary, ineffective, or harmful and that drive antimicrobial resistance.

inbiome’s answer is Molecular Culture®, a patented technology that skips growth altogether and reads bacterial DNA directly from the patient sample. Using proprietary IS-Pro chemistry — which combines length polymorphism of the 16S–23S rDNA region with phylum-specific fluorescent labeling — together with AI-driven data analysis, Molecular Culture® identifies more than 200 bacterial species at species level in roughly five hours and classifies unknown organisms to phylum level. It detects bacteria that cannot be cultured at all and remains informative even after antibiotic therapy has started. Because it is a broad, untargeted test rather than a panel of a few predefined targets, it also resolves polymicrobial samples in which multiple species are present simultaneously.

The test is validated across clinical samples where diagnostic delay matters most: whole blood, synovial, peritoneal, pleural, and pericardial fluids, cerebrospinal fluid, pus, and tissue and surgical wound biopsies. Molecular Culture® ID is IVDR-certified for use in European hospitals and has received FDA Breakthrough Device Designation, supporting entry into the United States. It runs on standard molecular laboratory equipment, so laboratories can adopt it without committing to a closed, proprietary system, and inbiome supports them with validation guidance, SOP integration, and audit-ready documentation.

Clinical evidence is building through collaborations with more than twenty hospitals in Europe and the United States, focused on the infections where culture most often falls short — joint and implant infections, sepsis, and infections in patients already on antibiotics — and on whether faster answers allow clinicians to start, narrow or stop treatment sooner. The company’s stated ambition is to make same-day infection diagnostics the standard of care by 2030.

Alongside the diagnostic platform, inbiome operates an ISO 13485-certified laboratory offering contract microbiology services: bacterial identification; quality-control testing of water, buffers, probiotics, and cosmetic products; and R&D support for hospitals, pharmaceutical and biotechnology companies, and food and beverage manufacturers.

Founded in 2019 and backed by the European Innovation Council, inbiome operates from Amsterdam Science Park and works with clinical, industrial, and academic partners across Europe and the United States. The goal is straightforward: give clinicians the right answer while there is still time to change the treatment.

 

inbiome logo
Contactpersoon
Dries Budding, CEO / Co-founder
Adres
Matrix SEVEN, Science Park 106, 1098 XH Amsterdam
Telefoonnummer
inbiome is a molecular diagnostics company at Amsterdam Science Park that is changing how bacterial infections are found and identified. Most hospitals still rely on culturing bacteria in the laboratory — a method more than a century old that takes two to five days and often fails entirely once a patient has received antibiotics. During that wait, physicians usually treat blindness with broad-spectrum antibiotics that may be unnecessary, ineffective, or harmful and that drive antimicrobial resistance.

inbiome’s answer is Molecular Culture®, a patented technology that skips growth altogether and reads bacterial DNA directly from the patient sample. Using proprietary IS-Pro chemistry — which combines length polymorphism of the 16S–23S rDNA region with phylum-specific fluorescent labeling — together with AI-driven data analysis, Molecular Culture® identifies more than 200 bacterial species at species level in roughly five hours and classifies unknown organisms to phylum level. It detects bacteria that cannot be cultured at all and remains informative even after antibiotic therapy has started. Because it is a broad, untargeted test rather than a panel of a few predefined targets, it also resolves polymicrobial samples in which multiple species are present simultaneously.

The test is validated across clinical samples where diagnostic delay matters most: whole blood, synovial, peritoneal, pleural, and pericardial fluids, cerebrospinal fluid, pus, and tissue and surgical wound biopsies. Molecular Culture® ID is IVDR-certified for use in European hospitals and has received FDA Breakthrough Device Designation, supporting entry into the United States. It runs on standard molecular laboratory equipment, so laboratories can adopt it without committing to a closed, proprietary system, and inbiome supports them with validation guidance, SOP integration, and audit-ready documentation.

Clinical evidence is building through collaborations with more than twenty hospitals in Europe and the United States, focused on the infections where culture most often falls short — joint and implant infections, sepsis, and infections in patients already on antibiotics — and on whether faster answers allow clinicians to start, narrow or stop treatment sooner. The company’s stated ambition is to make same-day infection diagnostics the standard of care by 2030.

Alongside the diagnostic platform, inbiome operates an ISO 13485-certified laboratory offering contract microbiology services: bacterial identification; quality-control testing of water, buffers, probiotics, and cosmetic products; and R&D support for hospitals, pharmaceutical and biotechnology companies, and food and beverage manufacturers.

Founded in 2019 and backed by the European Innovation Council, inbiome operates from Amsterdam Science Park and works with clinical, industrial, and academic partners across Europe and the United States. The goal is straightforward: give clinicians the right answer while there is still time to change the treatment.

 

Contactpersoon
Dries Budding, CEO / Co-founder
Adres
Matrix SEVEN, Science Park 106, 1098 XH Amsterdam